Sort
15,273 grants matching “antimicrobial resistance”
Role of the environmental sensor, AhR on colitis
$499,913Prakash S. Nagarkatti · University Of South Carolina At Columbia · R01 · FY2021 · AI
A synergy-based therapy against C. difficile
$499,908Kim Lewis · Northeastern University · R01 · FY2013 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** RECLAIMED WATER HAS BEEN CONSIDERED AN IMPORTANT ALTERNATIVE SOURCE WATER TO MITIGATE WATER SHORTAGE. HOWEVER, USING RECLAIMED WATER RELATED TO ANY HUMAN CONSUMPTION INCLUDING AGRICULTURAL AND FOOD PRODUCTION RAISES SERIOUS HEALTH CONCERNS. IN PARTICULAR, ELEVATED LEVELS OF PHARMACEUTICALS SUCH AS ANTIMICROBIALS AND AS WELL AS MICROPLASTICS SUCH AS MICROBEADS FROM COSMETOLOGY AND FIBERS FROM LAUNDRY ARE OFTEN OBSERVED IN TREATED WASTEWATER. TO ELUCIDATE THE INTERACTIVE EFFECTS BETWEEN MICROPLASTICS AND ANTIMICROBIALS IN AGROECOSYSTEMS, WE PROPOSE A FOUR-YEAR STUDY WITH THREE SPECIFIC OBJECTIVES: (1) ROLES OF MICROPLASTICS ON ANTIMICROBIALS (2) UPTAKES OF ANTIMICROBIALS IN THE PRESENCE OF MICROPLASTICS, AND (3) RISK REDUCTION STRATEGIES TO MITIGATE THEIR IMPACTS ON CROP PRODUCTION. THROUGH COLLABORATION WITH USDA-ARS, WE WILL CONDUCT MICROPLASTIC AND ANTIMICROBIAL SURVEYS FROM FIELD SITES THAT HAVE BEEN IRRIGATED WITH RECYCLED MUNICIPAL WASTEWATERS FOR LONG TERM. CONTROLLED LABORATORYSTUDIES WILL BE CARRIED OUT TO DETERMINE THE KINETICS OF DEGRADATION AND ADSORPTION-DESORPTION OF A VARIETY OF ANTIMICROBIALS WITH DIFFERENT TYPES OF MICROPLASTICS IN BOTH WASTEWATER AND SOIL WATER. MESOCOSM EXPERIMENTS WILL BE USED TO EXAMINE THE EFFECTS OF MICROPLASTICS-ANTIMICROBIALS INTERACTIONS ON SOIL MICROBES AND THEIR GAINING OF ANTIMICROBIAL RESISTANCE. GROWTH PERFORMANCE OF SELECTED CROPS IN GREENHOUSE ENVIRONEMNTS WILL BE EVALUATED UNDER THE INFLUENCES OF MICROPLASTICS AND ANIMICORBIALS. WE WILL ALSO TEST SOIL AMENDMENT AND IRRIGATION MANAGEMENT PRACTICES TO MITIGATE THE IMPACTS OF MICROPLASTICS AND ANTIMICROBIALS ON SOIL QUALITY AND PLANT GROWTH. A BOX MODEL DESCRIBING THE IMPACTS OF RECLAIMED WATERS IN AGROECOSYSTEMS WILL BE DEVELOPED AND CONVEYED TO REGULATORY AGENCIES AND DECISION-MAKERS.
$499,885Clemson University · · FY2020 · National Institute of Food and Agriculture
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib
$499,850Richard W Scott · Polymedix, Inc, · R44 · FY2010 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases
$499,839Eva Garland · Agile Sciences, Inc. · N01 · FY2018 · AI
Reducing Antimicrobial Overuse in HCAP Through Personalized Antimicrobial Recommendations
$499,650Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2015 · HS
Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates
$499,586Angela Marie Pollard · Agile Sciences, Inc. · R44 · FY2013 · DE
Mycobacterial Proteasome Inhibitors
$499,576Carl F Nathan · Weill Medical Coll Of Cornell Univ · R56 · FY2010 · AI
Southestern Pennsylvania Adult and Pediatric Prevention Epicenter Network
$499,569Ebbing Lautenbach · University Of Pennsylvania · U54 · FY2017 · CK
Human macrophage variation & TB pathogenesis
$499,471Thomas R Hawn · University Of Washington · U19 · FY2022 · AI
Staphylococcus aueaus vaccine development
$499,463Juliane Bubeck Wardenburg · University Of Chicago · U54 · FY2011 · AI
The role of GraRS in resistance to cationic antimicrobial peptides in S. aureus
$499,461Ambrose L. Cheung · Dartmouth College · R01 · FY2011 · AI
Hydrolysis-resistant resin networks for durable and multifunctional dental restorations
$499,440Jirun Sun · Ada Forsyth Institute, Inc. · R01 · FY2024 · DE
Rational Design of Inhibitors of Yersinia pestis EF-Tu
$499,432Molsoft, Llc · R43 · FY2004 · AI
Rational Design of Inhibitors of Yersinia pestis EF-Tu
$499,432Molsoft, Llc · R43 · FY2003 · AI
Microbiome in TB treatment response and disease resolution
$499,379Sabine Ehrt · Weill Medical Coll Of Cornell Univ · U19 · FY2022 · AI
Mycobacterial Proteasome Inhibitors
$499,329Carl F Nathan · Weill Medical Coll Of Cornell Univ · R56 · FY2009 · AI
ABCA1, ApoAI and Reverse Cholesterol Transport
$499,301Jonathan D Smith · Cleveland Clinic Lerner Com-Cwru · P01 · FY2014 · HL
Modeling Health System Infectious Disease Data
$499,291Susan S Huang · University Of California-Irvine · U01 · FY2010 · GM
Randomized Intervention for VesicolUreteral Reflux (RIVUR) Study
$499,273Ron Keren · Children'S Hosp Of Philadelphia · U01 · FY2010 · DK
Occupational Exposure and Health Risk from Dairy Microbiome and Resistome to Dairy Farm Workers
$499,260Gautam Dantas · Washington University · R01 · FY2018 · OH
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib
$499,244Richard W Scott · Polymedix, Inc, · R44 · FY2011 · AI
Phagosomal Ion Channels as Therapeutic Targets
$499,131Deborah J. Nelson · University Of Chicago · R01 · FY2015 · HL
Phagosomal Ion Channels as Therapeutic Targets
$499,131Deborah J. Nelson · University Of Chicago · R01 · FY2017 · HL
Phagosomal Ion Channels as Therapeutic Targets
$499,131Deborah J. Nelson · University Of Chicago · R01 · FY2016 · HL